期刊文献+

高效液相色谱法测定特立帕肽含量的方法研究

Study on HPLC determination of teriparatide
原文传递
导出
摘要 目的:建立HPLC测定特立帕肽含量的方法。方法:采用Kromasil C18(4.6 mm×250 mm,5μm)色谱柱,流动相为0.05mol·L^-1氯化钾溶液(磷酸调节至pH 4.5)-乙腈(75∶25),流速1.0 mL·min^-1;检测波长210 nm;柱温为室温;进样量20μL。结果:特立帕肽浓度在0.05-0.84 mg·mL^-1范围内具有良好的线性关系,r=0.9999。结论:本方法简便、准确,灵敏度高,重现性好,可用于测定特立帕肽的含量。 Objective:To develop an effective method for determination of teriparatide by HPLC.Methods:Teriparatide was determinated on HPLC instrument fixed with a Kromasil C18(4.6 mm×250 mm,5μm) column.The mobile phase was water with 0.05 mol·L^-1 KCl(adjusted to pH 4.5 with phosphoric acid)-acetonitrile(75∶25) at the flow rate of 1.0 mL· min^-1;The detector was set at 210 nm;Column temperature was room temperature,and the injection volume was 20 μL.Results:The calibration curve was linear(r=0.9999) within the range of 0.05-0.84 mg·mL^-1 for teriparatide.Conclusion:The method is simple,accurate,good sensitive,reproducible and is suitable for the determination of teriparatide
作者 余邦良 杨柳
出处 《药物分析杂志》 CAS CSCD 北大核心 2011年第5期980-982,共3页 Chinese Journal of Pharmaceutical Analysis
关键词 高效液相色谱法 特立帕肽 含量测定 HPLC teriparatide assay
  • 相关文献

参考文献6

  • 1Anastasilakis AD, Goulis DG, Polyzos SA, et al. Head - to - head comparison of risedronate vs teriparatide on bone tumovermarkers in women with postmenopausal osteoporosis a randomizedtrial, lnt J Clin Pract ,2008 ,62 ( 6 ) :919.
  • 2Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res ,2007,22( 1 ) : 149.
  • 3Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis treatment and discontinuation of therapy. Osteoporos lnt, 2005,16 (5) :510.
  • 4Kamp RM, Choli - Papadopoulou T. Protein Structure Analysis: Preparation, Characterization and nicrosecquencing(蛋白质结构分析:制备、鉴定和微量测序).Translated by SHI Yun - yu and RAO Zi-he(施蕴渝,饶子和译).Beijing(北京):Science Press(科学出版社),2002.50.
  • 5梁成罡,李克坚,张慧,杨化新,徐康森.重组人甲状旁腺激素的质量研究[J].药物分析杂志,2005,25(2):215-219. 被引量:7
  • 6ChP(中国药典).2010.VolⅡ(二部):922.

二级参考文献6

  • 1杨化新,张培培,徐康森.重组人生长激素胰肽图谱分析[J].药物分析杂志,1994,14(3):10-13. 被引量:11
  • 2Hendy GN, Kronenberg HM, Potts JT, et al. Nucleotide sequence of cloned cDNAs encoding human prepropamthyroid hormone. Proc Natl Acad Sci USA,1981,78(12) :7365.
  • 3Burtis W J, Wu T, Bunch C, et al. Identification of a novel 17000dalton parathyroid hormone- like adenylate cyclase- stimulationg protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem , 1987,262:7151.
  • 4Philbrick W M,WysolmerskiJ J,Galbraith S,et al. Defining the roles of parathyroid hormone related protein in normal physiolo gic. Physiolo Rev, 1996,76 : 127.
  • 5Fox J. Developments in parathyroid hormone and related peptides as bone - formation agents. Curt Opin Pharmacol,2002,2(3 ) :338.
  • 6Gonzatez EA, Disthabanchong S, Kowalewski R, et al. Mechanisms of the regtdation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106 -01 cells. Kidney Int, 2002,61 (5) :1627.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部